A systematic literature review was undertaken of articles reporting the internal reliability of the EORTC QLQ-BR23 to identify potential studies for inclusion. Internal reliability was assessed for each of the five domains of the EORTC QLQ-BR23: Body Image (BI), Sexual Functioning (SF), Arm Symptoms (AS), Breast Symptoms (BS) and Systemic Therapy Side Effects (ST). Reliability generalisation was undertaken using fixed and random effects models for each domain. A value for Cronbach's alpha coefficient above 0.70 was considered to indicate reliability.
The collection of patient-reported outcome (PRO) data is becoming more routine in oncology clinical trials and in clinical practice. The European Organisation for Research and Treatment of Cancer (EORTC) has developed and validated a number of PRO instruments, including the QLQ-BR23, a breast cancer specific measure 1 . The objective of this study was to evaluate the internal reliability of the EORTC QLQ-BR23 through reliability generalisation, a meta-analytic technique for pooling Cronbach's alpha coefficients.
A total of 15 studies were found resulting in 18 datasets. Of the 3,102 patients who had been recruited into studies 2,888 had completed the BR-23 (93%). Almost half the studies had used European language versions of the instrument (7/15, 47%). The unweighted average (fixed effects) Cronbach's alpha coefficient ranged from 0.69 (breast symptoms) to 0.86 (sexual functioning) ( Table 1) .
There was statistically significant heterogeneity present across the 5 domains under the fixed effects model justifying the use of random effects ( Table 1) . The random effects model accounted for the variance for the Body Image and Sexual Functioning domains, however, significant heterogeneity remained for the Arm and Breast Symptom domains, as well as the Systemic Therapy Side Effects domain. All Cronbach's alpha > 0.7 under the random effects model (Table 2, 
